Tympany Medical, the Galway company pioneering smarter surgical endoscopes, has launched a €600,000 fundraising campaign through Crowdcube under the Employment and Investment Incentive Scheme (EIIS).
With a 50% tax rebate available, the round targets both seasoned investors and first-time backers looking to diversify their investment portfolios and support innovation that improves lives.
Tympany Medical has developed Solascope, an endoscope platform targeting the 20 million procedures per annum requiring endoscopic visualisation.
Commencing in ENT Surgery, Tympany has developed cutting edge endoscope camera technology with variable-angle camera and integrated cleaning.
Building on the trend towards single-use, the company has developed a sustainable platform with minimal waste and optimum sterility and safety to benefit patients, surgeons and the environment.
Tympany Medical’s product enables shorter, less invasive surgical procedures, reducing recovery time for patients and enhancing surgical efficiency for medical teams.
“What’s innovative about our approach is that while the market is shifting from reusable to single-use devices for sterility and safety reasons, we’re introducing a single-use endoscope with a sterile, reusable handle,” said company Chairperson Charlie Wilhelm.
“This hybrid design significantly reduces medical waste in the operating room without compromising on patient outcomes or surgeon preference. This is a major sustainability win for healthcare.”
At the heart of Tympany Medical’s momentum is a bold leadership realignment. Co-founder and former CEO Dr Elizabeth McGloughlin has transitioned into the role of Vice President of Strategy, Clinical and Business Development.
This move recognised that sustainable scaling of the business requires a team-first approach.
“In fast-growing companies, especially in MedTech, leadership isn’t about titles, it’s about clarity and playing to strengths,” says Dr. McGloughlin.
“Stepping into a focused role where I can drive opportunity, partnerships, and business development has allowed us to accelerate growth.
“Appointing Michael Gilmore as CEO was a strategic decision; his business and engineering expertise perfectly complements my clinical background, and together, we’re strengthening the company’s performance and vision.”
“Our solution offers better visibility, improved ergonomics for surgeons, and more sustainable practice,” explains Gilmore. “We’re not just improving procedures; we’re reshaping what modern surgical tools should be.”
Now with 15 employees and a scalable roadmap, Tympany is poised for the next phase: commercial acceleration. The €600K investment is part of a larger €4.5 million round that will fund the company’s growth strategy, product refinement and early market deployment.
This campaign aims to accelerate Tympany Medical’s roadmap towards regulatory approvals, global partnerships and commercial readiness.
